Clinical Handbook of Psychotropic Drugs for Children and Adolescents

Prescribing Safely and Ethically to Children and Adolescents
Psychiatric Disorders in Children and Adolescents
Attention-Deficit/Hyperactivity Disorder (ADHD) * Major Depressive
Disorder (MDD) * Disruptive Mood Dysregulation Disorder (DMDD) * Bipolar
Disorder (BD) * Schizophrenia * ANXIETY DISORDERS * Separation
Anxiety Disorder * Generalized Anxiety Disorder (GAD) * Social Anxiety
Disorder * Panic Disorder * Specific Phobia * Obsessive-Compulsive Disorder
(OCD) * TRAUMA- AND STRESSOR-RELATED DISORDERS * Posttraumatic
Stress Disorder (PTSD) * TIC DISORDERS * Tourette's Disorder
* Autism Spectrum Disorder (ASD) * DISRUPTIVE, IMPULSE-CONTROL,
AND CONDUCT DISORDERS * Conduct Disorder (CD)
Oppositional Defiant Disorder (ODD)
Drugs for ADHD
Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD * ?2
Agonists * Augmentation Strategies in ADHD
Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine Dopamine
Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine Reuptake
Inhibitor (SNRI) * Serotonin-2 Antagonists/Reuptake Inhibitors (SARI)
* Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI) *
Serotonin Modulator and Stimulator (SMS) * Noradrenergic/Specific
Serotonergic Antidepressants (NaSSA) * Nonselective Cyclic Antidepressants
* Monoamine Oxidase Inhibitors * Reversible Inhibitor of
MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B) Inhibitors
(MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants on
Neurotransmitters/Receptors * Pharmacological Effects of Antidepressants
on Neurotransmitters/Receptors * Frequency of Adverse
Reactions to Antidepressants at Therapeutic Doses * Antidepressant
Doses and Pharmacokinetics * Switching Antidepressants * Antidepressant
Augmentation Strategies
Electroconvulsive Therapy (ECT)
Antipsychotics
"Second-Generation" Antipsychotics/SGAs * "Third-Generation" Antipsychotic/
TGA * "First-Generation" Antipsychotics/FGAs * Effects
of Antipsychotics on Neurotransmitters/Receptors* Pharmacological
Effects of Antipsychotics on Neurotransmitters/Receptors * Frequency
(%) of Adverse Reactions to Antipsychotics at Therapeutic Doses *
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting
Injections) * Comparison of Long-Acting IM Antipsychotics * Switching
Antipsychotics * Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects (EPSE) and Their
Management
Extrapyramidal Side Effects of Antipsychotics * Treatment Options for
Extrapyramidal Side Effects * Effects on Extrapyramidal Symptoms *
Comparison of Agents for Treating Acute Extrapyramidal Side Effects
* Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal
Side Effects
Anxiolytic (Antianxiety) Agents
Benzodiazepines * Comparison of the Benzodiazepines * Buspirone
Hypnotics/Sedatives
Comparison of Hypnotics/Sedatives
Mood Stabilizers
Lithium * Anticonvulsants * Comparison of Anticonvulsants * Frequency
of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
Drugs/Substances of Abuse
Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants/Aerosols
* Sodium Oxybate (Gamma-Hydroxybutyrate - GHB) * Flunitrazepam
(Rohypnol) * Nicotine/Tobacco
Treatment of Substance Use Disorders
Disulfiram * Acamprosate * Naltrexone * Methadone * Buprenorphine
* Pharmacotherapy for Nicotine/Tobacco Use Dependence
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents * Cholinergic Agents * Dopaminergic Agents * GABA
Agents/Anticonvulsants * Miscellaneous * NMDA Agents
Natural Health Products
Pharmacogenetic Information for Common Psychotropic Drugs
Management of Aggression in Children and Adolescents
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient and Caregiver Information Sheets
Index of Drugs